Preoperative and postoperative endotoxemia in children with congenital heart disease

Chest

Volumn 117, Issue 6, 2000, Pages 1706-1712

  Lequier, Laurance L ^a   Nikaidoh, Hisashi ^b   Leonard, Steven R ^b   Bokovoy, Joni L ^a   White, Mark L ^c   Scannon, Patrick J ^c   Giroir, Brett P ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

^c XOMA Corporation   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary bypass; Congenital heart disease; Endotoxin; Lipopolysaccharide binding protein

Indexed keywords

BINDING PROTEIN; ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ARTICLE; BLOOD LEVEL; CARDIOPULMONARY BYPASS; CONGENITAL HEART DISEASE; ENDOTOXEMIA; FEMALE; HEMODYNAMICS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; POSTOPERATIVE INFECTION; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0034097862     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.6.1706     Document Type: Article

References (40)

1. 1 Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet 1990; 2:294-295
2. 2 Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241
3. 3 Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994; 105:897-904
4. 4 Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998; 352:34-38
5. 5 Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201-1206
6. 6 Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92:1487-1493
7. 7 Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93:704-711
8. 8 Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97:175-183
9. 9 Kubota T, McTierman CF, Frye CS, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 1997; 3:117-124
10. 10 Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99:3224-3226
11. 11 Sliwa K, Skudicky D, Candy G, et al. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351:1091-1093
12. 12 Da Silva AMT, Kaulbach HC, Chuidian FS, et al. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1994; 328:1457-1460
13. 13 Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242
14. 14 Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159:195-204
15. 15 Murphy K, Haudek SB, Thompson M, et al. Molecular biology of septic shock. New Horiz 1998; 6:181-193
16. 16 Riddington DW, Venkatesh B, Boivin CM, et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996; 275:1007-1012
17. 17 Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997; 112:676-692
18. 18 Nilsson L, Kulander L, Nystrom SO, et al. Endotoxins in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 100:777-780
19. 19 Casey WF, Hauser GJ, Hannallah RS, et al. Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Crit Care Med 1992; 20:1090-1096
20. 20 Khabar KS, elBarbary MA, Khouqeer F, et al. Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clin Immunol Immunopathol 1997; 85:97-103
21. 21 Jansen NJ, van Oeveren W, Gu YJ, et al. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54:744-747
22. 22 Gallay P, Barras C, Tobias PS, et al. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J Infect Dis 1994; 170:1319-1322
23. 23 Schumann RR, Leong SR, Flaggs G, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249:1429-1431
24. 24 Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram negative sepsis. J Biol Chem 1989; 263:13479-13481
25. 25 Carroll SF, Dedrick R, White ML. Plasma levels of lipopolysaccharide binding protein (LBP) correlate with outcome in sepsis and other patients [abstract]. Shock 1997; 8:35
26. 26 Meszaros S, Aberle S, White M, et al. Immunoreactivity and bioactivity of lipopolysaccharide binding protein in normal and heat inactivated sera. Infect Immun 1995; 63:363-365
27. 27 Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants: a comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995; 92: 2226-2235
28. 28 Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure patients with and without peripheral oedema [abstract]. Eur Heart J 1998; 19:174
29. 29 Polin RA, Pollack PF, Barlow B, et al. Necrotizing enterocolitis in term infants. J Pediatr 1976; 89:460-462
30. 30 Martinez-Tallo E, Claure N, Bancalari E. Necrotizing enterocolitis in full-term or near-term infants: risk factors. Biol Neonate 1997; 71:292-298
31. 31 Millar AB, Armstrong L, van der Linden J, et al. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 1993; 56:1499-1502
32. 32 Dentener MA, Francot GJM, Hiemstra PS, et al. Bactericidal/permeability-increasing protein release in whole blood ex vivo: strong induction by lipopolysaccharide and tumor necrosis factor-a. J Infect Dis 1997; 175:108-117
33. 33 Dentener MA, Francot GJM, Smit FT, et al. Presence of bactericidal/permeability-increasing protein in disease: detection by ELISA. J Infect Dis 1995; 171:739-743
34. 34 Gazzano-Santoro H, Meszaros K, Birr C, et al. Competition between rBPI23, a recombinant fragment of bactericidal/ permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994; 62:1185-1191
35. 35 Watarida S, Mori A, Onoe M, et al. A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J Thorac Cardiovasc Surg 1994; 108:620-625
36. 36 Quigley RL, Caplan MS, Perkins JA, et al. Cardiopulmonary bypass with adequate flow and perfusion pressures prevents endotoxemia and pathologic cytokine production. Perfusion 1995; 10:27-31
37. 37 Bennett-Guerrero E, Ayuso L, Hamilton-Davies C, et al. Relationship of preoperative anti-endotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997; 277:646-650
38. 38 Biffl WL, Moore EE, Moore FA, et al. Interleukin-6 in the injured patient. Ann Surg 1996; 224:647-664
39. 39 Van der Poll T, van Deventer SJ. The role of interleukin-6 in endotoxin-induced inflammatory responses. Prog Clin Biol Res 1998; 397:365-377
40. 40 Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128:127-137